CytoDyn Inc. announced the appointment of Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs, effective November 20, 2026. The company entered into an Employment Agreement with Dr. Wilcoxen on November 17, 2026, which was approved by the Board of Directors on November 12, 2026.

Dr. Wilcoxen, age 40, brings extensive experience in regulatory affairs and clinical development, with a specific focus on oncology. Most recently, she served as Senior Vice President of Regulatory Affairs at Xilio Therapeutics, Inc. (NASDAQ: XLO). Prior to that, she held the position of Senior Vice President, Product Development and Regulatory Affairs at Checkpoint Therapeutics, Inc. (formerly NASDAQ: CKPT) from May 2022 to October 2025, where she helped secure FDA approval for a novel checkpoint inhibitor for skin cancer. She also previously served as Vice President of Regulatory Affairs at Istari Oncology, Inc. and provided consulting services through Clarivance Bio, LLC.

Dr. Wilcoxen will oversee the company’s oncology development strategy and regulatory affairs. In a statement, CEO Robert E. Hoffman noted that her expertise in navigating the FDA’s Division of Oncology and her familiarity with CytoDyn’s clinical programs, including the Phase 2 CLOVER study, make her well-suited to guide the company’s next stages of development.

Under the terms of the Employment Agreement, Dr. Wilcoxen’s initial compensation includes an annual base salary of $425,000. She is also eligible to participate in the company’s short- and long-term incentive plans, with a target annual bonus of 40% of her base salary for the fiscal year ending May 31, 2027. Additionally, she was awarded a nonqualified stock option to purchase 4,500,000 shares of the company’s common stock, which will vest over a four-year period. The agreement allows for termination at any time by either party, with or without cause, and includes severance benefits.